DK3071223T3 - Cell - Google Patents
Cell Download PDFInfo
- Publication number
- DK3071223T3 DK3071223T3 DK14806356.3T DK14806356T DK3071223T3 DK 3071223 T3 DK3071223 T3 DK 3071223T3 DK 14806356 T DK14806356 T DK 14806356T DK 3071223 T3 DK3071223 T3 DK 3071223T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70589—CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201320573A GB201320573D0 (en) | 2013-11-21 | 2013-11-21 | T Cell |
GB201410934A GB201410934D0 (en) | 2014-06-19 | 2014-06-19 | T cell |
PCT/GB2014/053453 WO2015075470A1 (en) | 2013-11-21 | 2014-11-21 | Cell |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3071223T3 true DK3071223T3 (da) | 2021-03-29 |
Family
ID=52003983
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14806356.3T DK3071223T3 (da) | 2013-11-21 | 2014-11-21 | Cell |
DK14806355.5T DK3071222T3 (da) | 2013-11-21 | 2014-11-21 | Celle |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14806355.5T DK3071222T3 (da) | 2013-11-21 | 2014-11-21 | Celle |
Country Status (20)
Country | Link |
---|---|
US (10) | US10172886B2 (da) |
EP (6) | EP3071222B1 (da) |
JP (4) | JP6538684B2 (da) |
KR (2) | KR101962524B1 (da) |
CN (2) | CN105848673B (da) |
AU (2) | AU2014351558B2 (da) |
BR (2) | BR112016011459A2 (da) |
CA (2) | CA2929984C (da) |
CL (2) | CL2016001135A1 (da) |
DK (2) | DK3071223T3 (da) |
ES (2) | ES2861501T3 (da) |
HK (2) | HK1223554A1 (da) |
HU (1) | HUE051523T2 (da) |
IL (2) | IL245572B (da) |
MX (2) | MX2016006057A (da) |
PL (2) | PL3071223T3 (da) |
PT (2) | PT3071223T (da) |
RU (2) | RU2732236C2 (da) |
SG (2) | SG11201603484PA (da) |
WO (3) | WO2015075468A1 (da) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102481378A (zh) | 2009-04-13 | 2012-05-30 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
PL3046583T3 (pl) | 2013-09-18 | 2019-10-31 | Aura Biosciences Inc | Koniugaty cząstek wirusopodobnych do leczenia nowotworów |
GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
SG11201603484PA (en) | 2013-11-21 | 2016-05-30 | Ucl Business Plc | Cell |
RU2701346C1 (ru) * | 2013-12-06 | 2019-09-25 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения |
US11885806B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
CN106536558A (zh) | 2014-04-10 | 2017-03-22 | 西雅图儿童医院(Dba西雅图儿童研究所) | 转基因遗传标签和使用的方法 |
EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
GB201415347D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
CA2969384A1 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain |
RU2768019C2 (ru) | 2014-12-24 | 2022-03-23 | Отолус Лимитед | Клетка |
CN107835820B (zh) * | 2015-01-26 | 2021-10-15 | 芝加哥大学 | 识别癌症特异性IL13Rα2的CAR T细胞 |
JP2018504143A (ja) | 2015-01-26 | 2018-02-15 | セレクティスCellectis | がん免疫治療のための抗hsp70特異的キメラ抗原受容体(car) |
CN114891816A (zh) | 2015-02-06 | 2022-08-12 | 新加坡国立大学 | 核酸、包含其的工程免疫细胞及其制备方法和用途 |
CN107249602B (zh) * | 2015-02-27 | 2021-09-28 | 美商生物细胞基因治疗有限公司 | 靶向血液恶性肿瘤之嵌合抗原受体(car)、其组合物及使用方法 |
SI3280729T1 (sl) | 2015-04-08 | 2022-09-30 | Novartis Ag | Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR) |
US10786549B2 (en) | 2015-04-23 | 2020-09-29 | Baylor College Of Medicine | CD5 chimeric antigen receptor for adoptive T cell therapy |
GB201507111D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
GB201507108D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
GB201507119D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
EP3288570A4 (en) * | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
CA2986030A1 (en) * | 2015-05-15 | 2016-11-24 | City Of Hope | Chimeric antigen receptor compositions |
JP6949728B2 (ja) * | 2015-05-29 | 2021-10-13 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法 |
GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
IL309167A (en) * | 2015-06-10 | 2024-02-01 | Immunitybio Inc | Modified NK-92 cells for cancer treatment |
US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
WO2017222593A1 (en) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
CN115058395A (zh) | 2015-06-25 | 2022-09-16 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
US11458167B2 (en) * | 2015-08-07 | 2022-10-04 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
GB201514874D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Cell |
GB201518817D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
CN108473950A (zh) * | 2015-10-30 | 2018-08-31 | 美国政府卫生与公众服务部 | 靶向癌症治疗 |
CA3016287A1 (en) * | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017193059A1 (en) | 2016-05-06 | 2017-11-09 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
WO2017201019A1 (en) * | 2016-05-17 | 2017-11-23 | Chimera Bioengineering, Inc. | Methods for making novel antigen binding domains |
JP7160482B2 (ja) * | 2016-09-02 | 2022-10-25 | レンティジェン・テクノロジー・インコーポレイテッド | Duocarを用いてがんを処置するための組成物および方法 |
GB2570063B (en) * | 2016-09-09 | 2022-11-02 | Crage Medical Co Ltd | Fusion protein and applications thereof |
US11219646B2 (en) * | 2016-09-30 | 2022-01-11 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
CA3039646A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
WO2018087557A1 (en) | 2016-11-11 | 2018-05-17 | Autolus Limited | Chimeric antigen receptor |
US10550183B2 (en) | 2016-11-22 | 2020-02-04 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
MX2019006631A (es) | 2016-12-12 | 2019-11-12 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas. |
CA3048648A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
WO2018183385A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
SG11201908337VA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
AU2018367896B2 (en) * | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
AU2018270078A1 (en) * | 2017-05-15 | 2019-11-07 | Autolus Limited | A cell comprising a chimeric antigen receptor (CAR) |
GB201707779D0 (en) | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
GB201707783D0 (en) * | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
AU2018313939A1 (en) | 2017-08-10 | 2020-02-06 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
BR112020006106A2 (pt) | 2017-09-28 | 2020-11-17 | Immpact-Bio Ltd. | métodos para identificar um alvo para preparar um receptor de antígeno quimérico inibidor ou um receptor de antígeno quimérico protetor e para tratar câncer em um paciente tendo um tumor, e, célula imune efetora segura |
EP3694886A4 (en) * | 2017-10-12 | 2021-09-22 | iCell Gene Therapeutics, LLC | COMPOSITE CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USING THEREOF |
WO2019084258A1 (en) | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | METHODS OF CONDITIONING BASED ON ANTI-CD45 AND USES THEREOF IN COMBINATION WITH GENETICALLY MODIFIED CELL THERAPIES |
GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
GB201803079D0 (en) * | 2018-02-26 | 2018-04-11 | Autolus Ltd | Cell |
US11813292B2 (en) | 2018-03-12 | 2023-11-14 | Immunity Bio, Inc. | Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity) |
AU2019269118A1 (en) | 2018-05-15 | 2020-12-03 | Autolus Limited | Chimeric antigen receptor |
GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
CN110615842B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含共刺激受体的嵌合抗原受体及应用 |
GB201813178D0 (en) | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
KR20210066865A (ko) | 2018-09-27 | 2021-06-07 | 오토러스 리미티드 | 키메라 항원 수용체 |
EP3632460A1 (en) * | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
US20220041687A1 (en) * | 2018-10-05 | 2022-02-10 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
EP3632461A1 (en) * | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
CN113164576A (zh) * | 2018-10-05 | 2021-07-23 | 圣安娜儿童癌症研究中心 | 嵌合抗原受体(car)组 |
GB201816522D0 (en) | 2018-10-10 | 2018-11-28 | Autolus Ltd | Methods and reagents for analysing nucleic acids from single cells |
CA3177829A1 (en) | 2018-12-12 | 2020-06-18 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
WO2020152197A1 (en) | 2019-01-23 | 2020-07-30 | Miltenyi Biotec B.V. & Co. KG | A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject |
EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
MX2021013225A (es) * | 2019-05-01 | 2022-01-06 | Pact Pharma Inc | Composiciones y metodos para el tratamiento del cancer utilizando una terapia de celulas t modificadas de cd8. |
GB201909144D0 (en) | 2019-06-25 | 2019-08-07 | Autolus Ltd | Culture medium |
WO2021009510A1 (en) | 2019-07-16 | 2021-01-21 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
GB201910185D0 (en) | 2019-07-16 | 2019-08-28 | Autolus Ltd | Method |
CN114585371A (zh) * | 2019-08-20 | 2022-06-03 | 森迪生物科学公司 | 嵌合抑制性受体 |
WO2021044213A2 (en) * | 2019-09-05 | 2021-03-11 | Migal-galilee Research Institute Ltd. | Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells |
US20240122979A1 (en) * | 2019-10-08 | 2024-04-18 | Provincial Health Services Authority | Chimeric Cytokine Receptors |
MX2022006962A (es) * | 2019-12-11 | 2022-09-12 | A2 Biotherapeutics Inc | Receptor quimerico de antigenos basado en el miembro 1 de la subfamilia b de receptores similares a inmunoglobulina de leucocitos (lilrb1). |
WO2021156277A1 (en) | 2020-02-04 | 2021-08-12 | Miltenyi Biotec B.V. & Co. KG | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens |
WO2021168298A1 (en) * | 2020-02-20 | 2021-08-26 | Senti Biosciences, Inc. | Inhibitory chimeric receptor architectures |
CN115397845A (zh) * | 2020-02-20 | 2022-11-25 | 森迪生物科学公司 | 抑制性嵌合受体架构 |
GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
EP3915578A1 (en) | 2020-05-28 | 2021-12-01 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor with a spacer comprising c2-set ig-like domains |
GB202008957D0 (en) | 2020-06-12 | 2020-07-29 | Autolus Ltd | Culture medium |
JP2023535371A (ja) | 2020-07-17 | 2023-08-17 | シミュレックス インコーポレイテッド | 免疫抑制シグナル伝達をリダイレクトするためのキメラMyD88受容体ならびに関連する組成物および方法 |
IL300497A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Compositions and methods for treating CEACAM-positive cancer |
MX2023002041A (es) | 2020-08-20 | 2023-04-27 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para mesotelina. |
CA3189510A1 (en) | 2020-08-20 | 2022-02-24 | Julyun OH | Compositions and methods for treating egfr positive cancers |
US20220089675A1 (en) * | 2020-09-21 | 2022-03-24 | A2 Biotherapeutics, Inc. | Engineered immune cells with dominant signals |
CN116648260A (zh) * | 2020-10-15 | 2023-08-25 | 小利兰·斯坦福大学董事会 | 用于抑制自然杀伤细胞受体的组合物和方法 |
EP4240404A1 (en) | 2020-11-09 | 2023-09-13 | Miltenyi Biotec B.V. & Co. KG | Methods and compositions for eliminating engineered immune cells |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
CN117597358A (zh) | 2021-02-16 | 2024-02-23 | A2生物治疗股份有限公司 | 用于治疗her2阳性癌症的组合物和方法 |
WO2023023602A1 (en) * | 2021-08-19 | 2023-02-23 | Boan Boston Llc | Fusion proteins for dephosphorylating proteins that regulate t cell activation through the tcr signaling pathway |
GB202112923D0 (en) | 2021-09-10 | 2021-10-27 | Ucl Business Ltd | Binding domain |
WO2023057285A1 (en) | 2021-10-06 | 2023-04-13 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
WO2023218381A1 (en) | 2022-05-11 | 2023-11-16 | Autolus Limited | Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia |
GB202209920D0 (en) | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
WO2024078995A1 (en) | 2022-10-15 | 2024-04-18 | Miltenyi Biotec B.V. & Co. KG | Transduction of gammadelta t cells with pseudotyped retroviral vectors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
US7052906B1 (en) | 1999-04-16 | 2006-05-30 | Celltech R & D Limited | Synthetic transmembrane components |
EP1334188B1 (en) * | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
US20030232430A1 (en) * | 2001-11-26 | 2003-12-18 | Advanced Cell Technology | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
WO2010085660A2 (en) * | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
DK3012268T3 (da) * | 2010-09-08 | 2018-02-19 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Chimeriske antigenreceptorer med en optimeret hængselregion |
CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
EP2968492B1 (en) * | 2013-03-15 | 2021-12-15 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
SG11201603484PA (en) | 2013-11-21 | 2016-05-30 | Ucl Business Plc | Cell |
CN106536558A (zh) * | 2014-04-10 | 2017-03-22 | 西雅图儿童医院(Dba西雅图儿童研究所) | 转基因遗传标签和使用的方法 |
GB201507119D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
GB201507115D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
-
2014
- 2014-11-21 SG SG11201603484PA patent/SG11201603484PA/en unknown
- 2014-11-21 US US15/037,414 patent/US10172886B2/en active Active
- 2014-11-21 ES ES14806356T patent/ES2861501T3/es active Active
- 2014-11-21 PL PL14806356T patent/PL3071223T3/pl unknown
- 2014-11-21 PL PL14806355T patent/PL3071222T3/pl unknown
- 2014-11-21 WO PCT/GB2014/053451 patent/WO2015075468A1/en active Application Filing
- 2014-11-21 HU HUE14806355A patent/HUE051523T2/hu unknown
- 2014-11-21 JP JP2016532594A patent/JP6538684B2/ja active Active
- 2014-11-21 US US15/037,405 patent/US10172885B2/en active Active
- 2014-11-21 CN CN201480063899.XA patent/CN105848673B/zh active Active
- 2014-11-21 RU RU2016124278A patent/RU2732236C2/ru active
- 2014-11-21 BR BR112016011459A patent/BR112016011459A2/pt not_active IP Right Cessation
- 2014-11-21 MX MX2016006057A patent/MX2016006057A/es active IP Right Grant
- 2014-11-21 KR KR1020167016454A patent/KR101962524B1/ko active IP Right Grant
- 2014-11-21 EP EP14806355.5A patent/EP3071222B1/en active Active
- 2014-11-21 WO PCT/GB2014/053453 patent/WO2015075470A1/en active Application Filing
- 2014-11-21 EP EP14806356.3A patent/EP3071223B1/en active Active
- 2014-11-21 EP EP19203534.3A patent/EP3626261A1/en not_active Withdrawn
- 2014-11-21 EP EP14806354.8A patent/EP3071221A1/en not_active Withdrawn
- 2014-11-21 EP EP21150742.1A patent/EP3858379A1/en active Pending
- 2014-11-21 AU AU2014351558A patent/AU2014351558B2/en active Active
- 2014-11-21 JP JP2016532581A patent/JP6433498B2/ja active Active
- 2014-11-21 DK DK14806356.3T patent/DK3071223T3/da active
- 2014-11-21 PT PT148063563T patent/PT3071223T/pt unknown
- 2014-11-21 EP EP20209028.8A patent/EP3858378A1/en active Pending
- 2014-11-21 DK DK14806355.5T patent/DK3071222T3/da active
- 2014-11-21 PT PT148063555T patent/PT3071222T/pt unknown
- 2014-11-21 MX MX2016006303A patent/MX2016006303A/es active IP Right Grant
- 2014-11-21 BR BR112016011460A patent/BR112016011460A2/pt not_active IP Right Cessation
- 2014-11-21 WO PCT/GB2014/053452 patent/WO2015075469A1/en active Application Filing
- 2014-11-21 KR KR1020167016452A patent/KR101991555B1/ko active IP Right Grant
- 2014-11-21 AU AU2014351557A patent/AU2014351557B2/en active Active
- 2014-11-21 ES ES14806355T patent/ES2832586T3/es active Active
- 2014-11-21 US US15/037,391 patent/US20160296562A1/en not_active Abandoned
- 2014-11-21 RU RU2016124280A patent/RU2717984C2/ru active
- 2014-11-21 CN CN201480063900.9A patent/CN105792840B/zh active Active
- 2014-11-21 CA CA2929984A patent/CA2929984C/en active Active
- 2014-11-21 SG SG11201603479TA patent/SG11201603479TA/en unknown
- 2014-11-21 CA CA2930215A patent/CA2930215C/en active Active
-
2016
- 2016-05-10 IL IL245572A patent/IL245572B/en active IP Right Grant
- 2016-05-10 IL IL245573A patent/IL245573B/en active IP Right Grant
- 2016-05-12 CL CL2016001135A patent/CL2016001135A1/es unknown
- 2016-05-12 CL CL2016001134A patent/CL2016001134A1/es unknown
- 2016-10-13 HK HK16111857.1A patent/HK1223554A1/zh unknown
- 2016-10-13 HK HK16111856.2A patent/HK1223553A1/zh unknown
-
2018
- 2018-08-10 US US16/100,832 patent/US20190038672A1/en not_active Abandoned
- 2018-12-25 JP JP2018240817A patent/JP2019041775A/ja not_active Withdrawn
-
2019
- 2019-04-23 US US16/392,250 patent/US20200016203A1/en not_active Abandoned
- 2019-04-26 US US16/395,754 patent/US20200016204A1/en not_active Abandoned
-
2020
- 2020-09-04 US US17/012,806 patent/US20210154229A1/en not_active Abandoned
- 2020-10-29 US US17/084,535 patent/US20210187026A1/en active Pending
- 2020-12-23 JP JP2020213272A patent/JP2021045172A/ja active Pending
-
2023
- 2023-01-23 US US18/158,310 patent/US20240033289A1/en active Pending
- 2023-05-22 US US18/321,517 patent/US20240033292A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3071223T3 (da) | Cell | |
DK3342773T3 (da) | Syk-hæmmere | |
DK3613453T3 (da) | Fordamper | |
UY4298S (es) | Carcasa | |
FR3003076B1 (fr) | Supercondensateur electrochimique | |
DK3077047T3 (da) | Aramcholsalte | |
DK3234476T3 (da) | Solfanger | |
DK3060460T3 (da) | Saddel | |
DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
DK2956698T3 (da) | Bindestrimler | |
DK3052081T3 (da) | Pastil | |
DK2946640T3 (da) | Langmuir-probe | |
DK3071227T3 (da) | Fiskevaccine | |
DE102013106534B8 (de) | Chromatographiepipettenspitze | |
DE112014001252A5 (de) | Aufbissschiene | |
DK2981168T3 (da) | Laminitiskile | |
DK3086679T3 (da) | Sportssko | |
ES1078715Y (es) | Mosquitera | |
UA28899S (uk) | Акумулятор | |
UA28818S (uk) | Акумулятор | |
UA28816S (uk) | Акумулятор | |
DE112014005422A5 (de) | Friktionsfalschdrallaggregat | |
UA28790S (uk) | Батарея | |
UA28290S (uk) | Акумулятор | |
UA28288S (uk) | Акумулятор |